Venus Concept to Release Second Quarter of Fiscal Year 2024 Financial Results on August 13, 2024
Venus Concept Inc. (NASDAQ: VERO), a global medical aesthetic technology leader, has announced the release date for its second quarter fiscal year 2024 financial results. The results will be unveiled before the market opens on Tuesday, August 13, 2024. Following the release, management will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly results and conduct a Q&A session.
Interested parties can participate in the call by dialing 877-407-2991 (201-389-0925 for international callers) and using the access code 13747737. A live webcast will also be available on the company's investor relations website. For those unable to attend, a two-week replay will be accessible via phone, and the webcast will be archived on the company's IR site.
- None.
- None.
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2024 financial results will be released before the market opens on Tuesday, August 13, 2024.
Management will host a conference call at 8:00 a.m. Eastern Time on August 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13747737. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13747737. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
FAQ
When will Venus Concept (VERO) release its Q2 2024 financial results?
How can investors participate in Venus Concept's Q2 2024 earnings call?
What time is Venus Concept's Q2 2024 earnings conference call scheduled for?